204 362

Cited 25 times in

Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer

DC FieldValueLanguage
dc.contributor.author노성훈-
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author신상준-
dc.contributor.author임종근-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.date.accessioned2015-05-19T17:25:51Z-
dc.date.available2015-05-19T17:25:51Z-
dc.date.issued2008-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/108133-
dc.description.abstractBACKGROUND: This phase II study describes the efficacy and safety of combination chemotherapy of 5-fluorouracil (5-FU), low-dose leucovorin, and oxaliplatin (FLOX regimen) for pretreated advanced gastric cancer. PATIENTS AND METHODS: Patients who had been previously treated with greater than or equal to one regimen were enrolled. Patients received an oxaliplatin 75 mg/m(2) on day 1, 5-FU 1000 mg/m(2) on days 1-3, and leucovorin 20 mg/m(2) on days 1-3, every 3 weeks. The primary end point was overall survival (OS). RESULTS: Among the 52 patients enrolled, 26 patients were treated as second line, and the remaining 26 patients were enrolled as third- or fourth line. A total of 203 cycles of chemotherapy were administered with the median being three cycles (range 1-15) per patient. The median OS was 6.6 months [95% confidence interval (CI) 4.5-8.8] and the median progression-free survival was 2.5 months (95% CI 1.9-3.0). The response rate was 4% (95% CI 0-9%), and the disease control rate was 48% (95% CI 34-62%). The most common toxic effects of grade 3/4 were neutropenia (16%) and vomiting (6%). CONCLUSIONS: The FLOX regimen showed modest activity as a salvage treatment in pretreated advanced gastric cancer with a favorable compliance.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1135~1140-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHLeucovorin/administration & dosage-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganoplatinum Compounds/administration & dosage-
dc.subject.MESHOxaliplatin-
dc.subject.MESHSalvage Therapy-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/mortality-
dc.subject.MESHStomach Neoplasms/pathology-
dc.titlePhase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJ. Jeong-
dc.contributor.googleauthorH.-C. Jeung-
dc.contributor.googleauthorS. Y. Rha-
dc.contributor.googleauthorC. K. Im-
dc.contributor.googleauthorS. J. Shin-
dc.contributor.googleauthorJ. B. Ahn-
dc.contributor.googleauthorS. H. Noh-
dc.contributor.googleauthorJ. K. Roh-
dc.contributor.googleauthorH. C. Chung-
dc.identifier.doi10.1093/annonc/mdn013-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01281-
dc.contributor.localIdA01290-
dc.contributor.localIdA02105-
dc.contributor.localIdA03402-
dc.contributor.localIdA03773-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.pmid18272910-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.keywordFemale-
dc.subject.keywordFluorouracil/administration & dosage-
dc.subject.keywordHumans-
dc.subject.keywordLeucovorin/administration & dosage-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordOrganoplatinum Compounds/administration & dosage-
dc.subject.keywordOxaliplatin-
dc.subject.keywordSalvage Therapy-
dc.subject.keywordStomach Neoplasms/drug therapy*-
dc.subject.keywordStomach Neoplasms/mortality-
dc.subject.keywordStomach Neoplasms/pathology-
dc.contributor.alternativeNameNoh, Sung Hoon-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameIm, Chong Kun-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.affiliatedAuthorNoh, Sung Hoon-
dc.contributor.affiliatedAuthorRoh, Jae Kyung-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorIm, Chong Kun-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsfree-
dc.citation.volume19-
dc.citation.number6-
dc.citation.startPage1135-
dc.citation.endPage1140-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.19(6) : 1135-1140, 2008-
dc.identifier.rimsid35206-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.